Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 90

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 90
---
 conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, as well as any new collaborations that we may enter into with third parties for our product candidates, the commercialization of our products or our product candidates, if approved, and any unforeseen cash needs. As a result, our management will have broad discretion in the application of the net proceeds from this offering, and the investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering.

Pending application of the net proceeds as described above, we intend to invest the net proceeds of this offering in short-term, investment-grade, interest-bearing securities.

<div align='center'>59

MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY</div>

Market Information

Our common stock is currently listed on the Nasdaq Capital Market under the symbol “MBIO”.

As of January 10, 2025, we had approximately 64,768,830 shares of common stock issued and outstanding held of record by approximately 72 registered holders.

Dividends

We have never declared or paid cash dividends on our common stock. We intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

<div align='center'>60</div>

CAPITALIZATION The following table sets forth our capitalization as of September 30, 2024 as follows:

| ● | on an actual basis; and |

| ● | on an as adjusted basis to reflect the issuance and sale by us of  up to            shares of common stock, pre-funded warrants to purchase up to             shares of common stock, Series C-1 Warrants to purchase up to             shares of common stock, Series C-2 Warrants to purchase up to             shares of common stock, and Series C-3 Warrants to purchase up to              shares of common stock in this offering at a public offering price of $             per share and accompanying Warrants and after deducting Placement Agent fees and estimated offering expenses